

Norgine B.V.

2019 Annual Report

Executive Summary

Norgine is a leading European specialist pharmaceutical company that has been **bringing transformative medicines to patients for over a century.**

Our commitment to transforming people's lives drives everything we do



Care

We constantly strive to understand how patients live and feel



Challenger mindset

We move rapidly and decisively to make things happen for them



Agile European infrastructure

Our European experience and exceptional partnership approach enable us to quickly deliver new, life-changing treatments



In 2019, we did more than ever to deliver on our commitment to patients



Helped
22 million
patients



Employed
1,500 people



Generated
€419m in net
product sales



Grew by **6%**


Our agile and well established European infrastructure means we deliver where others can't.

Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets.

We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure.

This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

Because patients inspire us



This growth was achieved predominantly through organic growth of Norgine’s products, including:




MOVICOL® maintained its leading position in Europe, generating more than €177.5 million in sales (2018: €160.3 million). **MOVICOL®** continues to be the European market leader in its class.



Two key products in Norgine's bowel cleansing franchise, **MOVIPREP®** and **PLENVU®**, achieved €74.0 million in sales in 2019, an increase of 15% over 2018.




XIFAXAN® (rifaxamin for the treatment of hepatic encephalopathy) continued to be the key growth driver for the group, with sales of €69.0 million in 2019, an increase of 13% over 2018.



Because patients inspire us

Norgine is a leading European specialist pharmaceutical company

01	Germany 23.4%	09	Switzerland 1.9%
02	United Kingdom 13.8%	10	Portugal 1.5%
03	France 11.2%	11	Ireland 1.6%
04	Spain 8.8%	12	Austria 0.8%
05	Italy 8.6%	13	Others (Europe) 3.6%
06	Scandinavia 3.8%	14	Australia 5.2%
07	Belgium 3.4%	15	Others (Non -Europe) 9.8%
08	The Netherlands 2.4%		



“Our commitment to patients has inspired us to adapt and innovate ever since the founding of Norgine in 1906.

Our long-term sustainable growth enables us to transform ever more patients’ lives. We will build on this exceptional foundation as a leading European specialist pharmaceutical company and create new partnerships and alliances to bring further innovative healthcare products to the European market.”



Peter Stein

Peter Stein, CEO, Norgine

Looking forward



We will work as one team to build our future by staying true to our 110 year heritage of adapting, innovating and growing.



Our focus for the future is clear - to work as one team to transform more lives by:

- Achieving long-term sustainable growth through being a partner of choice
- Attracting the best new talent and enabling all of our people to fulfill their potential

This is underpinned by our core values of One Norgine, Innovation and Trustworthiness.

Visit us at

 www.norgine.com

Follow us on social media

   [@Norgine](https://www.instagram.com/Norgine)